+ A prospective observational study was conducted in patients with new6onset RA.
respectively; absent/minimal PDA was detected in 62%, 66% and 67%, respectively. On multivariable analysis, shorter symptom duration, male gender, fewer tender joints and lower disability were associated with the clinical remission definitions. Lack of osteoarthritis predicted absence of PDA and lower total baseline PDA predicted absent/minimal PDA.
DAS286CRP remission and absence of PDA were observed in almost half of patients, but less than a quarter achieved both. Achievement of BR was rare. The low agreement between any of the clinical and imaging outcomes and differences in their predictors highlight the complex interaction between symptoms and synovitis, with implications for treat6to6target management. Long6term follow6up should determine the most appropriate target.
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Following a treat6to6target approach, 43% of patients with RA achieved DAS28 CRP remission in clinical practice.
In RA patients achieving DAS286CRP, DAS446CRP and 2011 ACR/EULAR remission, significant power Doppler activity was observed.
Objective measures of severe RA at baseline were associated with ongoing power Doppler at 12 months.
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Trials reveal patients with early rheumatoid arthritis (RA) achieve superior outcomes with treatment to target strategies in comparison to conventional routine care [163] . European
League Against Rheumatism (EULAR) guidelines recommend this approach [4, 5] .
Recommendations include monitoring disease activity using a composite measure at least every 3 months, with optimisation of treatment to achieve a pre6defined target, primarily remission. In 2011, American College of Rheumatology (ACR)/EULAR remission criteria were developed for use in trials [6] and are now recommended as the optimal target for treatment [4] . Two definitions are proposed, based on the simplified disease activity index (SDAI≤3.3) or that developed using a Boolean approach: swollen joint count (SJC), tender Adherence to guidelines was assessed by calculating the proportion of patients in whom
DAS286CRP4v was recorded at least every 3 months until achievement of the target Prevalence and bias adjusted kappa statistics were calculated to examine the relationship between the clinical remission endpoints and imaging outcomes. Univariable logistic regression was conducted to investigate factors associated with the clinical remission and imaging outcomes. Multivariable logistic regression analysis was also planned, entering baseline variables demonstrating statistical significance (p<0.05) on univariable analysis.
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Two6hundred and seventeen patients were eligible for inclusion in the analysis (Figure 1 ). No significant difference was observed between baseline DAS286CRP scores, DAS446CRP scores or ultrasound parameters in patients included in the analyses (n=105) and those who were lost to follow6up or in whom data was missing (n=112). However, they differed significantly (p<0.05) in the following manner: mean age was higher and SJC28, TJC28, SJC44 and RAI were generally lower amongst included patients (Table 1 ).
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The majority of patients commenced DMARDs at baseline (72%) or within the first 4 weeks (15%). Choice of first DMARD was methotrexate in 86%, hydroxychloroquine in 10% and sulphasalazine in 4% of patients. Methotrexate in combination with another DMARD was commenced in the remaining 1%. A contraindication to methotrexate was apparent in 5% of patients, including chronic obstructive airways disease, recent or concurrent infection and with methotrexate or an alternative DMARD, respectively, due to intolerance or an adverse event. Table 2 provides further details of patient management.
The DAS286CRP4v score was recorded at least every 3 months up to 12 months, or until the target was met, in 76 (72%) patients. Escalation of DMARDs (excluding corticosteroids) was appropriate (i.e. at least every 3 months if DAS286CRP4v≥2.6) in 53/76 (70%) of these patients. In a further 8 (10%) patients, corticosteroid therapy was escalated at least 36monthly. Amongst the remaining 15 patients in whom treatment was not escalated despite awareness of DAS286CRP4v≥2.6, reasons throughout the 12 months were: awaiting effect of previous treatment escalation (n=6), non6inflammatory symptoms only (n=5), acceptable disease control (n=4), contraindication to treatment escalation (n=2), patient declined (n=2), considered for biologic clinical trial (n=2) and isolated flare (n=1).
As the target DAS286CRP4v<2.6 allows the presence of clinical swelling [28] , there is still a role for clinical assessment as recommended within EULAR guidelines. In fact, out of 158 visits at which DAS286CRP4v<2.6 was observed, DMARD treatment was escalated due to a clinician impression of ongoing inflammatory disease activity at 26 (16%) visits.
At 12 months, rates of DAS286CRP4v remission (DAS286CRP4v<2.6) and low disease activity (DAS286CRP4v<3.2) were 43% and 60%; rates of DAS446CRP4v remission (DAS446CRP4v<1.6) and low disease activity (DAS446CRP4v<2.4) were 39% and 73%.
The rate of 2011 ACR/EULAR Boolean remission was 14%. The thirty patients achieving DAS286CRP4v<2.6 but not meeting the Boolean definition of remission missed the latter due to patient VASDA>10mm (n=23), TJC>1 (n=9), SJC>1 (n=6) and/or CRP>10mg/L (n=6).
In respect to ultrasound, absence of PDA (total PDA score=0) was observed in 42 (40%) patients at 12 months. Absent/minimal PDA, defined by a total PDA≤1, was observed in 60 (57%) patients. If any low6grade PDA (grade 1) at the wrists and/or first MTP joints was also accepted within the definition, seven additional patients achieved minimal PDA; i.e. 64% of patients demonstrated a total PDA score ≤1 excluding PDA=grade 1 at individual wrist and first MTP joints.
Amongst 70 patients attaining DAS286CRP4v<2.6 at least once over the 12 months, the median (IQR) time to first achievement of DAS286CRP4v<2.6 was 6 (369) months. In patients achieving DAS286CRP4v remission prior to month 12 (n=61), first DAS286CRP4v remission was sustained over the remaining follow6up in 27 (44%) patients. The majority of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In patients achieving DAS286CRP4v<2.6 with ongoing imaging evidence of synovitis (n=26),
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PDA was observed at the following sites: wrists (n=16), MCP263 (n=13), MTP1 (n=4), MTP26
5 (n=4), PIP263 (n=4), elbows (n=2) and the knee (n=1). In patients achieving Boolean remission the following joint regions were affected by PDA: MCP263 (n=5), wrists (n=4), MTP265 (n=1), PIP263 (n=1), and elbows (n=1).
In patients lacking any PDA, but with active disease as indicated by DAS286CRP4v≥2.6 (n=23), median (IQR) values for the DAS28 component variables were TJC28 5(269), SJC28 1(062), patient VASDA 57(40657) mm and CRP 9(0618) mg/dL. Amongst 36 patients lacking any PDA but not achieving Boolean remission, patient VASDA>10mm was the most frequent preclusion to fulfilment of the Boolean criteria (n=32), followed by TJC53>1 (n=24), CRP>10mg/dL (n=15) and SJC44>1 (n=9).
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Univariable analyses demonstrated achievement of the various clinical remission outcomes was significantly associated with male gender, shorter symptom duration, fewer tender joints and lower HAQ at baseline (Table 4 ). In comparison, baseline parameters predictive of achievement of imaging outcomes were lack of coexistent osteoarthritis, seronegativity, fewer swollen joints, lower CRP and lower total PDA score on ultrasound. A lower DAS286CRP3v score at baseline was significantly associated with all outcomes. Excluding
PDA=grade 1 at the wrists and/or first MTP joints in the definition of absent/minimal PDA did 
! $ !
This large single6centre, contemporary study reveals that at 12 months almost half of patients with new6onset RA achieve the clinical target (DAS286CRP remission) in daily practice, using EULAR treatment6to6target recommendations as a guide to management. [44] . Moreover, the likelihood that the presence of tender joints and a high patient global assessment which may be influenced by a complex interaction of factors other than active synovitis (such as chronic pain, side6effects of treatment and the presence of comorbidity) is also relevant, particularly given the characteristics which were evident in these patients.
Baseline predictors of clinical remission outcomes were male gender, shorter symptom duration, fewer tender joints, and lower patient VASDA and HAQ scores. In contrast, lack of osteoarthritis and objective signs of less severe disease (RF and ACPA negativity, fewer clinically swollen joints, and lower CRP and baseline PDA) were associated with favourable imaging outcomes. The latter parameters are arguably more reflective of the primary pathology, active synovitis. Therefore, logically, they should warrant aggressive treatment or treatment escalation if present or if increased above normal levels. These findings, therefore, support current and future research into the use of imaging within the management of early RA.
The strengths of this study are its considerable size for a single6centre study. All assessors were trained, supervised and working within one clinic, limiting variation in prescribing behaviour. Management and data collection conducted in an out6patient clinic setting and the absence of strict inclusion criteria afford a degree of generalisability to daily practice. Of note, the prevalence of comorbidities was significant. Greater than one in ten patients in this real6life cohort displayed a contraindication to commencement of methotrexate or intolerance to it necessitating cessation. In addition, one in twenty patients failed an alternative DMARD to methotrexate. patients with unfavourable subjective factors were less likely to achieve the clinical remission outcomes, whereas factors more directly indicative of inflammatory disease activity predicted persistent active disease on imaging. Failure to achieve absent/minimal PDA was associated with higher PDA at baseline. As persistence of PDA in clinical remission is associated with poor outcomes[9611] the baseline PDA is a warning. Ultrasound may therefore prove to be a useful tool in discerning an individual's prognosis at diagnosis as well as assessing inflammation on treatment.
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We acknowledge other members of the Leeds Musculoskeletal Biomedical Research Unit for their contribution to data collection, including sonographers Laura Horton and Alwyn Jackson, and Elizabeth Hensor for statistical advice. Möttönen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single6drug or combination-disease6modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 2002; 46(4) Values are number of patients (percentage of patients), unless otherwise stated. a 2011 ACR/EULAR Boolean remission (swollen joint count (SJC44) ≤1, tender joint count (TJC53) ≤1, CRP≤10mg/dL and patient VASDA≤10mm).
b Sum of PDA semi6quantitative score assessed in 26 joints (PDA graded between 0 and 3 for each joint, maximum total score 78). PDA: power Doppler activity, PABAK: prevalence and bias adjusted kappa, DAS286CRP4v: disease activity score using 4 variables (SJC28, TJC28, CRP and patient VASDA), DAS446CRP4v: disease activity score using 4 variables (SJC44, RAI, CRP and patient VASDA). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
